TGFB1 and COVID-19: Beyond post-COVID-19 sequelae, therapies such as autologous EBV- or SARS-CoV-2-specific T cells engineered to resist TGFβ or immunosuppression58 or antivirals that limit EBV replication could help to alleviate virus-induced hyperinflammation.